Rochester, NY-Bausch & Lomb will delay the regulatory filing for the intravitreal fluocinolone acetonide implant (Retisert), a treatment for diabetic macular edema (DME), for up to 3 years while the FDA reviews 12-month safety data of additional eyes treated with implants.
